BioCentury | Apr 15, 2013
Clinical News

Novastan argatroban small molecule thrombin inhibitor data

...to be announced at the International Society of Thrombosis and Hemostasis meeting on June 12. Texas Biotechnology Corp....
BioCentury | Apr 15, 2013
Clinical News

Texas Biotech regulatory update

...Canada as an anticoagulant therapy for patients with heparin-induced thrombocytopenia (HIT) (see BioCentury, Aug. 11). Texas Biotechnology Corp....
BioCentury | Apr 15, 2013
Company News

Pharmacopeia, Texas Biotech deal

...will share revenues from lead compounds discovered under the collaboration. Pharmacopeia Inc. (PCOP), Princeton, N.J. Texas Biotechnology Corp....
BioCentury | Oct 23, 2006
Strategy

Icos chronicles

...Discontinues joint development of endothelin receptor antagonists through Icos-Texas, a JV between ICOS and Texas Biotech. Texas Biotech...
BioCentury | Jan 12, 2004
Emerging Company Profile

Revotar: Sum of the parts

...its expertise in inflammation, rational drug design, and preclinical and early clinical development. ENCY (formerly Texas Biotechnology Corp....
BioCentury | Apr 28, 2003
Company News

Icos, Texas Biotech deal

...in the endothelin antagonist joint venture (see BioCentury, Feb. 3). Icos Corp. (ICOS), Bothell, Wash. Texas Biotechnology Corp....
BioCentury | Apr 28, 2003
Finance

Ebb & Flow

...Brown as vice president of clinical development, a job he formerly held at cardiovascular play Texas Biotech...
BioCentury | Apr 28, 2003
Company News

Lexicon Genetics Inc. management update

...Genomics Hired: Philip Brown as VP of clinical development, formerly VP of clinical development at Texas Biotechnology Corp. WIR...
BioCentury | Mar 17, 2003
Clinical News

Argatroban synthetic thrombin inhibitor regulatory update

...interventions (PCI). Argatroban was developed by TXBI and is marketed in the U.S. by GSK. Texas Biotechnology Corp....
BioCentury | Mar 10, 2003
Product Development

Actelion: BREATHE to BUILD growth

...drug works in several PAH subpopulations (see "Actelion Market Opportunity," A9). One possible competitor is Texas Biotech...
Items per page:
1 - 10 of 169
BioCentury | Apr 15, 2013
Clinical News

Novastan argatroban small molecule thrombin inhibitor data

...to be announced at the International Society of Thrombosis and Hemostasis meeting on June 12. Texas Biotechnology Corp....
BioCentury | Apr 15, 2013
Clinical News

Texas Biotech regulatory update

...Canada as an anticoagulant therapy for patients with heparin-induced thrombocytopenia (HIT) (see BioCentury, Aug. 11). Texas Biotechnology Corp....
BioCentury | Apr 15, 2013
Company News

Pharmacopeia, Texas Biotech deal

...will share revenues from lead compounds discovered under the collaboration. Pharmacopeia Inc. (PCOP), Princeton, N.J. Texas Biotechnology Corp....
BioCentury | Oct 23, 2006
Strategy

Icos chronicles

...Discontinues joint development of endothelin receptor antagonists through Icos-Texas, a JV between ICOS and Texas Biotech. Texas Biotech...
BioCentury | Jan 12, 2004
Emerging Company Profile

Revotar: Sum of the parts

...its expertise in inflammation, rational drug design, and preclinical and early clinical development. ENCY (formerly Texas Biotechnology Corp....
BioCentury | Apr 28, 2003
Company News

Icos, Texas Biotech deal

...in the endothelin antagonist joint venture (see BioCentury, Feb. 3). Icos Corp. (ICOS), Bothell, Wash. Texas Biotechnology Corp....
BioCentury | Apr 28, 2003
Finance

Ebb & Flow

...Brown as vice president of clinical development, a job he formerly held at cardiovascular play Texas Biotech...
BioCentury | Apr 28, 2003
Company News

Lexicon Genetics Inc. management update

...Genomics Hired: Philip Brown as VP of clinical development, formerly VP of clinical development at Texas Biotechnology Corp. WIR...
BioCentury | Mar 17, 2003
Clinical News

Argatroban synthetic thrombin inhibitor regulatory update

...interventions (PCI). Argatroban was developed by TXBI and is marketed in the U.S. by GSK. Texas Biotechnology Corp....
BioCentury | Mar 10, 2003
Product Development

Actelion: BREATHE to BUILD growth

...drug works in several PAH subpopulations (see "Actelion Market Opportunity," A9). One possible competitor is Texas Biotech...
Items per page:
1 - 10 of 169